Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US drug maker Lexicon Pharmaceuticals has concluded a placebo-controlled, randomized Phase 1 trial evaluating LX1033 as a treatment for diarrhea-predominant irritable bowel syndrome (IBS-d).
Subscribe to our email newsletter
The trial results suggested that the drug was well tolerated at all dose levels and showed reduction in serotonin synthesis compared to placebo.
The data from the study demonstrated that LX1033 showed prominent decrease in both plasma and urinary 5-HIAA in comparison to placebo at all doses tested.
The company is planning to move this drug into Phase 2 trial in patients suffering from IBS-d.
Lexicon senior vice president and chief medical officer Pablo Lapuerta said they look forward to advancing this drug into a Phase 2 trial where we can examine safety and efficacy in IBS-d.